Cargando…
Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial
Reduced intensity conditioning (RIC) transplantation is increasingly offered to older patients with acute myeloblastic leukemia. We have previously shown that a RIC allograft, particularly from a sibling donor, is beneficial in intermediate-risk patients aged 35-65 years. We here present analyses fr...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244837/ https://www.ncbi.nlm.nih.gov/pubmed/34647442 http://dx.doi.org/10.3324/haematol.2021.279010 |
_version_ | 1784738612395376640 |
---|---|
author | Russell, Nigel H. Hills, Robert K. Thomas, Abin Thomas, Ian Kjeldsen, Lars Dennis, Mike Craddock, Charles Freeman, Sylvie Clark, Richard E. Burnett, Alan K. |
author_facet | Russell, Nigel H. Hills, Robert K. Thomas, Abin Thomas, Ian Kjeldsen, Lars Dennis, Mike Craddock, Charles Freeman, Sylvie Clark, Richard E. Burnett, Alan K. |
author_sort | Russell, Nigel H. |
collection | PubMed |
description | Reduced intensity conditioning (RIC) transplantation is increasingly offered to older patients with acute myeloblastic leukemia. We have previously shown that a RIC allograft, particularly from a sibling donor, is beneficial in intermediate-risk patients aged 35-65 years. We here present analyses from the NCRI AML16 trial extending this experience to older patients aged 60-70 inclusive lacking favorable-risk cytogenetics. Nine hundred thirty-two patients were studied, with RIC transplant in first remission given to 144 (sibling n=52, matched unrelated donor n=92) with a median follow-up for survival from complete remission of 60 months. Comparisons of outcomes of patients transplanted versus those not were carried out using Mantel-Byar analysis. Among the 144 allografted patients, 93 had intermediate-risk cytogenetics, 18 had adverse risk and cytogenetic risk group was unknown for 33. In transplanted patients survival was 37% at 5 years, and while the survival for recipients of grafts from siblings (44%) was better than that for recipients of grafts from matched unrelated donors (34%), this difference was not statistically significant (P=0.2). When comparing RIC versus chemotherapy, survival of patients treated with the former was significantly improved (37% versus 20%, hazard ratio = 0.67 [0.53-0.84]; P<0.001). When stratified by Wheatley risk group into good, standard and poor risk there was consistent benefit for RIC across risk groups. When stratified by minimal residual disease status after course 1, there was consistent benefit for allografting. The benefit for RIC was seen in patients with a FLT3 ITD or NPM1 mutation with no evidence of a differential effect by genotype. We conclude that RIC transplantation is an attractive option for older patients with acute myeloblastic leukemia lacking favorable-risk cytogenetics and, in this study, we could not find a group that did not benefit. |
format | Online Article Text |
id | pubmed-9244837 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Fondazione Ferrata Storti |
record_format | MEDLINE/PubMed |
spelling | pubmed-92448372022-07-07 Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial Russell, Nigel H. Hills, Robert K. Thomas, Abin Thomas, Ian Kjeldsen, Lars Dennis, Mike Craddock, Charles Freeman, Sylvie Clark, Richard E. Burnett, Alan K. Haematologica Article - Acute Myeloid Leukemia Reduced intensity conditioning (RIC) transplantation is increasingly offered to older patients with acute myeloblastic leukemia. We have previously shown that a RIC allograft, particularly from a sibling donor, is beneficial in intermediate-risk patients aged 35-65 years. We here present analyses from the NCRI AML16 trial extending this experience to older patients aged 60-70 inclusive lacking favorable-risk cytogenetics. Nine hundred thirty-two patients were studied, with RIC transplant in first remission given to 144 (sibling n=52, matched unrelated donor n=92) with a median follow-up for survival from complete remission of 60 months. Comparisons of outcomes of patients transplanted versus those not were carried out using Mantel-Byar analysis. Among the 144 allografted patients, 93 had intermediate-risk cytogenetics, 18 had adverse risk and cytogenetic risk group was unknown for 33. In transplanted patients survival was 37% at 5 years, and while the survival for recipients of grafts from siblings (44%) was better than that for recipients of grafts from matched unrelated donors (34%), this difference was not statistically significant (P=0.2). When comparing RIC versus chemotherapy, survival of patients treated with the former was significantly improved (37% versus 20%, hazard ratio = 0.67 [0.53-0.84]; P<0.001). When stratified by Wheatley risk group into good, standard and poor risk there was consistent benefit for RIC across risk groups. When stratified by minimal residual disease status after course 1, there was consistent benefit for allografting. The benefit for RIC was seen in patients with a FLT3 ITD or NPM1 mutation with no evidence of a differential effect by genotype. We conclude that RIC transplantation is an attractive option for older patients with acute myeloblastic leukemia lacking favorable-risk cytogenetics and, in this study, we could not find a group that did not benefit. Fondazione Ferrata Storti 2021-10-14 /pmc/articles/PMC9244837/ /pubmed/34647442 http://dx.doi.org/10.3324/haematol.2021.279010 Text en Copyright© 2022 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
spellingShingle | Article - Acute Myeloid Leukemia Russell, Nigel H. Hills, Robert K. Thomas, Abin Thomas, Ian Kjeldsen, Lars Dennis, Mike Craddock, Charles Freeman, Sylvie Clark, Richard E. Burnett, Alan K. Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial |
title | Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial |
title_full | Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial |
title_fullStr | Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial |
title_full_unstemmed | Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial |
title_short | Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial |
title_sort | outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the ncri acute myeloid leukemia 16 trial |
topic | Article - Acute Myeloid Leukemia |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244837/ https://www.ncbi.nlm.nih.gov/pubmed/34647442 http://dx.doi.org/10.3324/haematol.2021.279010 |
work_keys_str_mv | AT russellnigelh outcomesofolderpatientsaged60to70yearsundergoingreducedintensitytransplantforacutemyeloblasticleukemiaresultsofthencriacutemyeloidleukemia16trial AT hillsrobertk outcomesofolderpatientsaged60to70yearsundergoingreducedintensitytransplantforacutemyeloblasticleukemiaresultsofthencriacutemyeloidleukemia16trial AT thomasabin outcomesofolderpatientsaged60to70yearsundergoingreducedintensitytransplantforacutemyeloblasticleukemiaresultsofthencriacutemyeloidleukemia16trial AT thomasian outcomesofolderpatientsaged60to70yearsundergoingreducedintensitytransplantforacutemyeloblasticleukemiaresultsofthencriacutemyeloidleukemia16trial AT kjeldsenlars outcomesofolderpatientsaged60to70yearsundergoingreducedintensitytransplantforacutemyeloblasticleukemiaresultsofthencriacutemyeloidleukemia16trial AT dennismike outcomesofolderpatientsaged60to70yearsundergoingreducedintensitytransplantforacutemyeloblasticleukemiaresultsofthencriacutemyeloidleukemia16trial AT craddockcharles outcomesofolderpatientsaged60to70yearsundergoingreducedintensitytransplantforacutemyeloblasticleukemiaresultsofthencriacutemyeloidleukemia16trial AT freemansylvie outcomesofolderpatientsaged60to70yearsundergoingreducedintensitytransplantforacutemyeloblasticleukemiaresultsofthencriacutemyeloidleukemia16trial AT clarkricharde outcomesofolderpatientsaged60to70yearsundergoingreducedintensitytransplantforacutemyeloblasticleukemiaresultsofthencriacutemyeloidleukemia16trial AT burnettalank outcomesofolderpatientsaged60to70yearsundergoingreducedintensitytransplantforacutemyeloblasticleukemiaresultsofthencriacutemyeloidleukemia16trial |